Research programme: toll-like receptor antagonist - Janus Biotherapeutics/Roche

Drug Profile

Research programme: toll-like receptor antagonist - Janus Biotherapeutics/Roche

Alternative Names: JB6121; TLR inhibitor - Janus Biotherapeutics/Roche; Toll-like receptor inhibitor - Janus Biotherapeutics/Roche

Latest Information Update: 05 Jan 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Janus Biotherapeutics
  • Developer Janus Biotherapeutics; Roche
  • Class Small molecules
  • Mechanism of Action Toll-like receptor 7 antagonists; Toll-like receptor 8 antagonists; Toll-like receptor 9 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Systemic lupus erythematosus

Most Recent Events

  • 20 Aug 2015 Janus Biotherapeutics and Roche agree to co-develop TLR Antagonist in USA for Autoimmune Disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top